SGN-CD33A: Phase Ib started

Seattle Genetics began an open-label, dose-escalation, U.S. Phase Ib trial of IV SGN-CD33A in about 90 newly diagnosed patients. Patients will receive SGN-CD33A in combination with a standard dose of ...